Prof. Dr. How Soon Hin


Pulmonologist
International Islamic University, Malaysia

Prof. Dr. How Soon Hin qualified from University Malaya, Kuala Lumpur in 1996 and obtained Master in Internal Medicine at the same university in 2002. He is currently working as Professor of Medicine, Kulliyyah of Medicine, International Islamic University. He also works as consultant general physician and chest physician in IIUM Medical Centre, Hospital Tengku Ampuan Afzan and Darul Makmur Medical Centre.

He has special interest in endobronchial ultrasound guided biopsy (EBUS–TBNA), rigid bronchoscopy, navigational bronchoscopy, endobronchial tumour debulking, metallic and silicone stenting. Prof. How’s research interests focus on melioidosis and lung cancer. He also involved in multi-centre randomized control study on asthma, chronic obstructive pulmonary disease and lung cancer.



Abstract

Making advanced Non-Small Cell Lung Cancer (NSCLC) into chronic disease: What scientists can do?

Lung cancer is one of the most common cancer, it accounts for about 10% of all cancer cases but associated with 20% of cancer mortality. Most lung cancer patients presented at the late stages. In Malaysia, 90% of them were diagnosed with either stage III or IV at presentation. In the era of chemotherapy, overall survival of treated advanced NSCLC was 9-12 months. The discovery of driver mutation eg. EGFR, ALK, ROS 1 significantly prolong its survival. In profile 1014 study, median overall survival of ALK positive NSCLC patient treated with ALK inhibitors was extended to more than 4 years. In the same study, patients treated with chemotherapy without ALK inhibitor were associated with poorer outcome. In the recent years, immunotherapy had been showed to prolong overall survival of patients with NSCLC without driver mutation. Some of patients who were given immunotherapy had durable response and possible cure. With discovery of more therapeutic agents, better molecular diagnostic tools and improvement in efficacy of current treatment, advanced NSCLC may become chronic disease in future. Scientists play an important role to achieve this goal.